A61K 2239/22
Intracellular domain
A61K2239/22 (Intracellular domain) appears on 82 US grants and 522 published applications in this corpus.
Search patents in A61K- Granted patents
- 82
- Published applications
- 522
- Assignees
- 286
- Inventors
- 1,443
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 0 |
| 2012 | 0 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 3 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 3 | 3 |
| 2018 | 0 | 10 |
| 2019 | 0 | 7 |
| 2020 | 2 | 15 |
| 2021 | 5 | 17 |
| 2022 | 7 | 21 |
| 2023 | 11 | 72 |
| 2024 | 16 | 149 |
| 2025 | 16 | 130 |
| 2026 | 19 | 88 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Cell/gene therapies targeting MAGE-A4 peptide21 Jul 2026US 12,685,774 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Coreceptor chimeric antigen receptor24 Sep 2026US 2026/0284111 A1
- Anti-cldn18.2 antibodies and diagnostic uses thereof24 Sep 2026US 2026/0284112 A1Antengene Biologics Limited
Most cited
By later US patents
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Modified cell line and method for expansion of NK cell123US 7,435,596 B2St. Jude Children?S Research Hospital · 2008
- Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy108US 9,745,368 B2Novartis AG · 2017
- Expansion of NK cells and therapeutic uses thereof72US 8,026,097 B2St. Jude Children?S Research Hospital · 2011
- Chimeric receptors with 4-1BB stimulatory signaling domain72US 9,834,590 B2St. Jude Children?S Research Hospital · 2017